Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
February 12 2021 - 1:56PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of February 2021
Commission
File Number 001-15170
GlaxoSmithKline plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
GlaxoSmithKline plc (the 'Company')
2021 Awards under the Deferred Investment Award
Programme
Notional Award
On 10 February 2021, the Company granted awards over notional
Ordinary Shares to Persons Discharging Managerial Responsibilities
('PDMRs') under the GlaxoSmithKline Deferred Investment Award
programme.
Under the programme, awards are made over notional Ordinary Shares
with vesting phased over a specified period to provide long-term
alignment with shareholders. Vesting is subject to the PDMR
not having served the Company notice or having been terminated by
the Company for cause. Dividends will accrue on the award
during the vesting period through reinvestment in additional
notional shares. On vesting, the award and accrued dividends will
be paid in cash. Executive Directors are not eligible to receive
awards under the programme.
The awards have been made to support the retention of the PDMRs
listed below. The awards will vest 50% on 10 February 2024,
25% on 10 February 2025, and the balance on 10 February
2026.
The closing Ordinary Share price on 10 February 2021, used to
determine the awards, was £12.75.
Transaction notification
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr R Connor
|
|
b)
|
Position/status
|
President, Global Vaccines
|
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description of the financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the transaction
|
A restricted award of notional Ordinary Shares under the Company's
Deferred Investment Award programme.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
|
£12.75
|
78,431.373
|
|
d)
|
Aggregated information
Aggregated volume
Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2021-02-10
|
|
f)
|
Place of the
transaction
|
n/a
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr L Miels
|
|
b)
|
Position/status
|
President, Global Pharmaceuticals
|
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description of the financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the transaction
|
A restricted award of notional Ordinary Shares under the Company's
Deferred Investment Award programme.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
|
£12.75
|
78,431.373
|
|
d)
|
Aggregated information
|
n/a (single transaction)
|
|
Aggregated volume
Price
|
|
|
e)
|
Date
of the transaction
|
2021-02-10
|
|
f)
|
Place of the
transaction
|
n/a
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr R Simard
|
|
b)
|
Position/status
|
President, Pharmaceuticals Supply Chain
|
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description of the financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the transaction
|
A restricted award of notional Ordinary Shares under the Company's
Deferred Investment Award programme.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
|
£12.75
|
39,215.686
|
|
d)
|
Aggregated information
Aggregated volume
Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2021-02-10
|
|
f)
|
Place of the
transaction
|
n/a
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Ms D Waterhouse
|
|
b)
|
Position/status
|
CEO of ViiV Healthcare
|
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description of the financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the transaction
|
A restricted award of notional Ordinary Shares under the Company's
Deferred Investment Award programme.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
|
£12.75
|
78,431.373
|
|
d)
|
Aggregated information
Aggregated volume
Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2021-02-10
|
|
f)
|
Place of the
transaction
|
n/a
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: February
12, 2021
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|
GSK (PK) (USOTC:GLAXF)
Historical Stock Chart
From Dec 2024 to Jan 2025
GSK (PK) (USOTC:GLAXF)
Historical Stock Chart
From Jan 2024 to Jan 2025
